[HTML][HTML] The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from …
SB Marley, MWN Deininger, RJ Davidson… - Experimental …, 2000 - Elsevier
OBJECTIVE: To determine whether the compound STI571 (formerly known as
CGP571418B), a selective inhibitor of the protein tyrosine kinase (PTK) activity of ABL and
BCR-ABL proteins, preferentially reduces the capacity for amplification of granulocyte-
macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia while
sparing normal CFU-GM and to compare responses of CML and normal cells with STI571
and IFN-α. MATERIALS AND METHODS: Chronic phase CML and normal CFU-GM were …
CGP571418B), a selective inhibitor of the protein tyrosine kinase (PTK) activity of ABL and
BCR-ABL proteins, preferentially reduces the capacity for amplification of granulocyte-
macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia while
sparing normal CFU-GM and to compare responses of CML and normal cells with STI571
and IFN-α. MATERIALS AND METHODS: Chronic phase CML and normal CFU-GM were …